Introduction
Erectile function involves a coordinated interaction of the vascular, endocrine, and nervous systems, the end result of which is cGMP-mediated increased inflow of blood to the penis, a concomitant decrease of venous outflow, and production of an erection. 1 Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection of the penis sufficient to permit satisfactory sexual intercourse, and can be due to psychogenic, vascular, and/or neurogenic disorders. 2 It is estimated that ED affects 10 to 30 million men in the US and more than 140 million men worldwide. 3, 4 The goal of the treatment of ED is to produce an erection sufficient for vaginal penetration and lasting long enough for subject and partner satisfaction. The most commonly used pharmacological treatment of ED today is sildenafil (Viagra s ), an inhibitor of the type-V cGMP-specific phosphodiesterase (PDE5). Sildenafil facilitates an erection by inhibiting the natural catabolism of cGMP. 5 Depending upon the etiology and severity of the ED, patients report success rates that range from 48 to 70%. 6 Side effects such as headache, flushing, and changes in color vision contribute to reasons cited for discontinuation of use. Owing to the potentiation of hypotension by the combination of sildenafil and organic nitrates, sildenafil is contraindicated in patients taking organic nitrates. Second-generation PDE5 inhibitors approved or currently under consideration for approval in the US include Levitra s (Vardenafil) 7 and Cialis s (Tadalafil, IC351) 8 , respectively. The identification of alternative ED treatments is an area of active investigation, as Viagra s and other PDE5 inhibitors are not tolerated by some patients, are contraindicated in patients taking organic nitrates, and are ineffective in a significant number of patients.
Melanotan-II (MT-II), a nonselective melanocortin receptor agonist, has been previously evaluated by Wessells et al. 9 MT-II was shown to be an inducer of penile erections, with a strong erectile response observed in 17 of 20 men with psychogenic and/or organic ED. However, yawning, stretching, and nausea were reported, with severe nausea occurring following 4 of 19 (21%) MT-II injections. These observations, in conjunction with the delayed time to onset of erectile activity of approximately 2 h, precluded further evaluation of MT-II as a pharmacological agent to treat ED. Discovery and subsequent development of PT-141 were predicated on the need for a molecule that possesses efficacy comparable to MT-II, but with an improved tolerability profile and a more rapid onset of action. PT-141 is a cyclic heptapeptide melanocortin analog that is being evaluated as an intranasally (i.n.) administered treatment for ED. PT-141 is an active metabolite of MT-II that lacks an amide at the carboxyl-terminus, and has the following aminoacid sequence: Ac-Nle-cyclo (-Asp-His-D-Phe-ArgTrp-Lys-OH).
Results from pharmacology studies demonstrate PT-141 to be an agonist at melanocortin receptors MC3-R and MC4-R, which are primarily expressed in the central nervous system (A Shadiack, manuscript in preparation).
The present study evaluated the safety, tolerability, efficicacy, and pharmacokinetics of single doses of PT-141 administered i.n. to healthy male subjects and to ED patients. Other phase 2 trials recently completed have investigated alternative routes of PT-141 administration and efficacy in treatmentresistant patients. Results of these studies are presented elsewhere (manuscript in preparation).
Materials and methods

Study population
Subjects in both studies underwent a complete medical history, physical examination, clinical laboratory tests (including chemistry, hematology, urinalysis, and urine drug screen), and a resting 12-lead ECG within 21 days prior to administration of study medication.
In the Phase 1 Study, eligible subjects were healthy males, between 18 and 45 y of age, inclusive, and within 20% of ideal weight, without any history of ED, penile abnormalities, or other clinically significant abnormalities.
In the Phase 2A Study, eligible patients were adult males between 18 and 65 y of age, inclusive, with a diagnosis of ED and who had been treated successfully with Viagra s within at least the last 6 months and were current users of Viagra s upon enrollment into the study. Successful treatment with Viagra s was defined for this study by attainment of an erection sufficient for vaginal penetration Z50% of the time while taking Viagra s . These criteria insured that patients were physiologically capable of erectile activity upon enrollment into the study. The etiology of ED was not defined for individual patients. The exclusion criteria included ED caused by untreated endocrine disease, anatomic deformations of the penis, prostatic disorders, or evidence of clinically significant hepatic, renal, cardiovascular, psychiatric, or CNS disease, including stroke or spinal cord injury. A human ethics committee approved the study protocol and informed consent document for each study prior to the enrollment of research subjects, and all volunteers gave written informed consent prior to their participation in the study. Both studies were conducted in compliance with a written protocol and applicable FDA regulations and ICH guidelines to insure adherence to Good Clinical Practice standards and regulatory requirements.
Study design and procedures
Study medication
In the Phase 1 Study, PT-141 (or matching placebo) was administered as an i.n. spray at doses of 4, 7, 10, or 20 mg. Subjects were dosed in the morning following an overnight fast and were kept under observation until 12 h postdose.
In the Phase 2A Study, PT-141 (or matching placebo) was administered as an i.n. spray at doses of 7 or 20 mg approximately 1 h after breakfast, and patients were kept under observation until 12 h postdose.
Pharmacokinetic procedures
In the Phase 1 Study, serial blood samples for determination of plasma PT-141 concentration were obtained predose and at 0.5, 1, 2, 4, and 8 h postdose. In the Phase 2A Study, blood samples for determination of PT-141 plasma levels were drawn predose and 45 min postdose. Plasma levels of PT-141 were quantified according to a validated HPLC-MS/MS analysis method.
Pharmacodynamic (RigiScant) procedures
In both studies, penile rigidity (erectile response) was measured using the RigiScant Plus Rigidity Assessment System (Endocare, Eden Prairie, Minnesota, USA), which continuously measures penile response through displacement of sensor loops at the tip and base of the penis. In the Phase 1 Study, Figure 1 .
Safety assessments
In At approximately 12 h after dosing, an abbreviated physical examination and a resting 12-lead ECG were performed, and blood and urine were obtained for clinical safety laboratory tests (chemistry, endocrinology, hematology, and urinalysis).
In the Phase 2A Study, vital signs (sitting, immediate standing and 2-min standing blood pressure and pulse rate) were measured predose, after the completion of the RigiScant penile rigidity monitoring session (approximately 155 min postdose) and prior to discharge (approximately 12 h postdose). An abbreviated physical exam and a resting 12-lead ECG were performed approximately 12 h postdose on the last visit, prior to discharge from the study. Blood and urine were obtained for clinical safety laboratory tests (chemistry, endocrinology, hematology, and urinalysis) at 12 h postdose on the last visit, prior to discharge from the study.
Pharmacokinetic and statistical analyses
Pharmacokinetic measurements were analyzed using noncompartmental models. The area under the drug concentration curve from zero to the last postdose quantifiable plasma concentration level (AUC (0-t) ), maximum plasma concentration (C max ), time to maximum plasma concentration (T max ), and apparent half-life (t 1/2 ) were calculated for plasma PT-141 concentration data using nonparametric methods with WinNonlin, Version 3.2 (Pharsight Corporation, Mountain View, California, USA).
For the RigiScant data, the total duration of erections with Z60% rigidity at the base and tip of the penis was summarized, as calculated using the RigiScant Plus software. Sustained erectile activity, a time-intensity assessment, was expressed as RAU and TAU and summarized descriptively. The pharmacodynamic effect of PT-141 was analyzed using a one-way analysis of variance (ANOVA). Comparisons between PT-141 doses and placebo were made using least-square means and a one-tailed t-test Effects of i.n. PT-141 on ED LE Diamond et al when applying either ANOVA or mixed effect models.
For the Phase 2A Study, total duration of erections with Z60% rigidity at the base of the penis, as calculated using the RigiScant Plus software, was analyzed using ANOVA. The mixed effect model was employed to evaluate the effect of treatment, sequence (treatment path), and period (visit). Total duration of erections with Z60% rigidity at the tip of the penis and RAU and TAU were analyzed using a similar mixed effect model.
Safety was assessed through monitoring of vital signs, physical exams, laboratory data, ECG evaluations, and reported adverse events (AEs). Clinically significant vital sign changes were defined by a change, compared to predose values, in systolic blood pressure of 430 mmHg, or in diastolic blood pressure 420 mmHg, or in pulse rate 430 b.p.m. Safety data were summarized for all subjects receiving each PT-141 dose and placebo separately. Statistical analyses were generated using SAS, Version 6.12 or 8.0 (SAS Institute, Cary, North Carolina, USA).
Results
Subjects
Subject demographic characteristics for both studies are summarized in Table 1 . In the Phase 1 Study, 32 eligible male subjects were enrolled, randomized, received a single dose of PT-141 at 4, 7, 10, or 20 mg (six subjects per dose level), or matching placebo (two subjects per dose level) and completed the study. Dose groups were demographically comparable for both mean and range with respect to age, weight, height, and race (data not shown).
In the Phase 2A Study, 24 eligible male patients with ED were enrolled, randomized, and received PT-141 7 mg, 20 mg, and matching placebo in a three-way crossover manner, and completed all scheduled study visits. All patients had a documented diagnosis of ED, with a mean duration of 6.2 y, and were Viagra s responsive by self-report. The mean of the individual responses regarding the efficacy of Viagra s was 65%, meaning that, on average, Viagra s enabled subjects to achieve an erection sufficient for vaginal penetration twice for every three times the medication was taken and intercourse attempted. All patients produced an active prescription for at least 50 mg Viagra s . Comorbidities included smoking, diabetes mellitus, hypertension, and hyperlipidemia. All patients completed the International Index of Erectile Function (IIEF) questionnaire 10 at the screening visit. Although the IIEF score is not validated under the conditions of current Viagra s use, the mean (s.d.) baseline IIEF erectile function domain score of 18.3 (6.3) was consistent with a population of patients with moderate ED who are being successfully treated with PDE5 pharmacotherapy. 11 Viagra s use (50 mg for 33% of the patients and 100 mg for 67% of 
Pharmacodynamic (erectile response) effect
A clear pharmacodynamic effect, manifested as a clinically and statistically significant erectile response that was assessed using a RigiScant plethysmography device, was observed both in healthy male subjects and in Viagra s -responsive ED patients. Relative to placebo, this erectogenic response was statistically significant at i.n. PT-141 doses above 7 mg, and was observed for the duration of base and tip penile rigidity X60%, as well as for base and tip RAU and TAU (Table 2) . Arithmetic mean (s.e.) of rigidity and tumescence criteria at the base and tip of the penis following single-dose administration of placebo or PT-141 to healthy male subjects (Phase 1 Study) and to ED patients (Phase 2A Study).
Effects of i.n. PT-141 on ED LE Diamond et al
In the Phase 1 Study (Figure 3 ), erectile responses increased in a dose-dependent manner between 7 and 20 mg of PT-141. The administration of 10 and 20 mg of PT-141 resulted in a significantly greater duration of base rigidity X60% compared to placebo (Po0.05, Po0.001, respectively). The effect of the 4 mg dose was indistinguishable from placebo and 4 mg can be considered a no effect dose. Mean duration of base rigidity X60% increased from 49.4 to 137.7 min for subjects receiving the 7-20 mg PT-141 doses, compared to 20.6 min for subjects receiving placebo. Mean duration of X60% tip rigidity ranged from 41.1 to 126.6 min for subjects receiving the 7-20 mg PT-141 dose levels, compared to 5.3 min for subjects receiving placebo (Table 2) . It is worth noting that this dose-dependent pharmacodynamic effect was observed in healthy males in the absence of VSS or any other form of stimulation.
Based upon visual inspection of the RigiScant event data, the time to onset of the first erection of X60% base rigidity persisting for at least 3 consecutive minutes decreased in a dose-dependent manner. First erections occurred approximately 30 min after administration of 20 mg i.n. PT-141 (Figure 3, inset) .
In the Phase 2A Study, a clinically significant erectile response was observed in ED patients following single-dose PT-141 administration in the presence of VSS relative to placebo (Table 2) . Compared to placebo, there was evidence of an increase in the erectile response at the 7 mg dose of PT-141, while the 20 mg PT-141 dose resulted in a significantly greater duration of base rigidity Z60% (Po0.001) and Z80% (Po0.01) (Figure 4 ). Mean duration of Z60% base rigidity was 26.0 and 53.8 min for patients receiving the 7 and 20 mg PT-141 doses, respectively, compared to 18.5 min for patients receiving placebo. Mean duration of base rigidity at Z80% was 6.3 and 23.8 min for subjects receiving the 7 and 20 mg PT-141 doses, respectively, compared to 7.2 min for patients receiving placebo.
Based upon visual inspection of the RigiScant event data in these ED patients, the mean time to onset of the first erection of Z60% base rigidity persisting for a minimum of 3 consecutive minutes occurred 35 min after PT-141 administration (data not shown).
Low-responder analysis. RigiScant monitoring was not employed as a screening tool in the Phase 2A study to exclude patients based upon erectile activity in response to VSS. However, eight of the 24 ED patients were retrospectively classified as low responders defined by an inability to achieve an erection Z20% base rigidity for a minimum of 3 consecutive minutes during the first 30 min of VSS after administration of placebo. This subgroup was not apparently different from the intent-to-treat group by any other demographic characteristic (ie age, IIEF score, ED duration, or comorbidities). Ad hoc analysis of the RigiScant evaluations of the low-responder group demonstrated a significant (Po0.05) increase in the erectile response, as measured by Z60 and Z80% base rigidity, at the 20 mg dose ( Figure 5 ). Mean total duration of X60% base rigidity was measured at 9.0 and 32.0 min for the 7 and 20 mg dose groups, respectively, compared to 2.4 min for the placebo group. Mean total duration of Z80% base rigidity was measured at 0.5 and 18.5 min for the 7 and 20 mg dose groups, respectively, compared to 0.7 min for the placebo group. This subpopulation of patients, which had a markedly diminished baseline erectile response to VSS and likely a greater degree of ED, was able to respond to VSS with erections considered sufficient for sexual intercourse after administration of 20 mg i.n. PT-141. 
Safety and tolerability
Single doses up to 20 mg PT-141 were safely administered to healthy male subjects and ED patients and were well tolerated. In the Phase 1 Study, the most common AEs reported in healthy males receiving PT-141 were flushing, nausea, feeling hot, and taste disturbance. One subject vomited after administration of 20 mg PT-141 (Table 3 ). All AEs were mild in nature, with the exception of one subject who experienced moderate flushing, and all AEs resolved without treatment or intervention. Compared to predose evaluations, no clinically significant changes in blood pressure, heart rate, or ECG evaluations were observed. In the Phase 2A Study, the most common AE following the 7 mg dose of PT-141 was flushing, and the most common AEs following the 20 mg dose of PT-141 were nausea and flushing. No subjects vomited in the Phase 2A Study (Table 3 ). All AEs were mild and self-resolving. Flushing after PT-141 administration was cephalic in nature and does not appear to be due to vasodilation as no concomitant blood pressure decreases were observed. The four subjects that experienced nausea after administration of 20 mg of PT-141 showed more than a two-fold increase in X60% base rigidity as compared to their individual responses to VSS after placebo treatment. Compared to baseline evaluations, no clinically significant changes in blood pressure, heart rate, or ECG evaluations were observed during the study.
No clinically relevant changes were noted in endocrine status, clinical chemistry, hematology and urinalysis tests, or physical examinations in either study. No subjects discontinued participation due to an AE and no subjects experienced a serious AE.
Discussion
Elucidation of the mechanisms involved in the initiation of an erection has allowed the development of targeted therapies, specifically inhibition of cGMP catabolism mediated by phosphodiesterase. Sildenafil (Viagra s ), a potent PDE5 inhibitor, is the first effective oral drug marketed for the treatment of ED. Second-generation PDE5 inhibitors, which may provide greater specificity and potency, and/or longer duration of action, have shown promising results in clinical trials. 7, 8 Information available from clinical trials using sublingual apomorphine, a centrally acting dopaminergic receptor agonist, suggests that it may be an alternative for patients with ED. 12, 13 However, apomorphine has a narrow therapeutic window and syncopal events have been reported, particularly when ethanol is coadministered.
PT-141 is a synthetic peptide analog of a-MSH. a-MSH is one of several melanocortins that arise from post-translational processing of a precursor peptide proopiomelanocortin (POMC).
14 In the (n¼8), defined by the inability to achieve Z20% base rigidity for at least 3 consecutive minutes during 30 min of VSS after administration of placebo.
Patients were treated with placebo, 7 and 20 mg PT-141. *Po0.05; **Po0.01; ***Po0.001. The studies reported demonstrate for the first time the erectogenic properties of i.n. administered PT-141, a synthetic peptide with efficacy in both normal male subjects and in ED patients, at doses that are safe and well tolerated. RigiScant evaluation showed that PT-141 produced a statistically significant and dose-dependent increase in duration of penile base rigidity measured at greater than 60%, and other RigiScant parameters, when compared to placebo. This response occurred in the absence of VSS in healthy male subjects, a unique finding for compounds currently available or under development for the treatment of ED. This finding is consistent with an initiator function of PT-141 in the induction of erectile activity, as compared to the facilitating activity of PDE5 inhibitors.
The time to onset of the first erection following i.n. PT-141 administration, either in the absence or presence of stimulation, was approximately 30 min, consistent with patient requirements for at-home use.
A subset analysis was performed on RigiScant data collected from ED patients who were retrospectively identified as low responders, as defined by an inability to achieve greater than 20% base rigidity for at least 3 consecutive minutes during 30 min of VSS after treatment with placebo. Results of this analysis demonstrated that a 20 mg dose of PT-141, in the presence of VSS, generated a clinically and statistically significant erectile response in these low-responder ED patients.
There was no assessment of effect on libido in this study nor were any direct comparisons made between PT-141 and other ED medications.
There is debate as to the correlation of radial rigidity, as measured by the RigiScant Plus Rigidity Assessment System, and the degree of axial rigidity, or penile buckling force, sufficient for penetrative intercourse. 18 It has been reported that measurements taken at the base of the penis, as compared to tip measurements, correlate with buckling pressure. 19 Furthermore, it has been demonstrated that most patients who experience Z60% base rigidity in the clinical setting will achieve an erection sufficient for sexual intercourse in an at-home environment. 20, 21 As a tool to evaluate efficacy of a potential ED therapy, it is generally accepted that RigiScant evaluations offer the ability to objectively test the degree of rigidity and tumescence of erections in a quantifiable and reproducible manner. Utilization of RigiScant evaluation in healthy male subjects treated with i.n. PT-141 or placebo was appropriate in this study based upon the fact that PT-141, with a central mechanism of action, is directly erectogenic. This is in contrast to, for instance, PDE5 inhibitors, which act to maintain erectile activity and would therefore not be expected to show activity in normal, unstimulated subjects. The low background of erectile activity measured in normal male subjects after administration of placebo may be attributable to minor stimulation by the RigiScant apparatus.
The optimal ED pharmacotherapy profile includes prompt onset of action, reliability of efficacy, sufficient duration of action after a single dose, and a good tolerability and safety profile. Oral dosing of PT-141 is not feasible since PT-141 would be quickly degraded in the gastrointestinal tract. Results from pharmacokinetic analysis showed a dose-dependent increase in systemic exposure upon i.n. administration of PT-141. Absolute bioavailability was calculated to be approximately 14% (data not shown). As demonstrated after administration of 20 mg i.n. PT-141 to healthy male subjects and ED patients, the initiation of erectile activity occurs within approximately 30 min of dosing, erection time (with no ejaculation events) at X60% base rigidity exceeded 2 h (during a 6.5 h evaluation) in healthy males in the absence of VSS, and lasted approximately 1 h (during a 2.5 h evaluation) in ED patients in the presence of VSS, and adverse events experienced by subjects were predominantly mild in nature. The pharmacokinetic and pharmacodynamic data collected in these studies indicates that PT-141 is a promising candidate for further evaluation as an ED therapy.
